Scholars World Heart Congress

Progress in reducing the number of deaths related to cardiovascular disease has been waning in recent years, heightening concerns that the obesity epidemic in the United States is undoing improvements in heart health. A research letter published Tuesday in Journal of the American Medical Association confirms that although the death rates from heart disease, diabetes, stroke and related disorders have been decreasing for decades, the rates have recently slowed or stalled. “At best, progress has slowed to a halt, and, at worst, our rates of cardiovascular disease are going up,” said Steven Nissen, chief academic officer for the Heart and Vascular Institute at Cleveland Clinic. “And the cause, pretty much everybody agrees, is the obesity epidemic and all of its downstream consequences.” More than 93 million adults and nearly 14 million children and adolescents in the United States are considered to be obese — a number that has been climbing for decades, according

A guide to reducing risks and living well even if you develop the condition Congestive heart failure is a serious illness. But it does not, as is sometimes thought, mean the heart stops ­altogether. It signifies that the muscle is damaged and can no longer pump enough blood to meet the body’s needs. This condition, which ­affects 1 in 5 adults—usually in the later years—can shorten life. But with proper treatment, people are living longer and better with heart failure. “We have more medications at our disposal today to improve quality of life for people with a weakened heart,” says Guy L. Mintz, M.D., director of cardiovascular health and lipidology at Sandra Atlas Bass Heart Hospital in Manhasset, N.Y. Here’s what to do. Coronary artery disease and heart attacks are major causes of heart failure, says cardiologist Tamara Horwich, M.D., medical director of UCLA’s cardiac rehabilitation program in Los Angeles. Managing your risk for problems—such as high blood pressure, h

A polypill combining four cheap cardiovascular medicines substantially reduces the risk of serious heart disease, the concept’s first large clinical trial has shown.  An international team led by Tehran University of Medical Sciences in collaboration with the University of Birmingham in the UK followed 6,840 middle-aged people in north-eastern Iran over five years. Half took a daily polypill and the rest received only healthy lifestyle advice. The findings, published in The Lancet, showed 201 major cardiovascular events, notably heart attack, stroke and heart failure, among those who took the polypill and 310 in the non-using control group. Taking polypills cut the risk of such cardiovascular events by 40 per cent in people with no history of heart disease and by 20 per cent in those with previous symptoms. “The idea of the polypill has always been appealing, and now we know that a fixed-dose polypill can achieve clinical benefits in practice,” said Professor Reza Malekzadeh, proje

Robert J. DiDomenico, PharmD, FCCP, FHFSA, FACC, who is Associate Professor, Cardiovascular Clinical Pharmacist at the University of Illinois at Chicago College of Pharmacy, brought the 2019 Directions in Pharmacy conference to a close. He discussed improving transitions of care for patients who have heart failure, with an emphasis on the pharmacist’s role. This topic is timely because 6.2 million adults in the United States are currently diagnosed with heart failure. Experts estimate that by 2030, heart failure’s prevalence will increase by 46%. Among adults aged 45 to 95 years, the lifetime risk is 20% to 45%. In the United States, heart failure and its associated transitions of care are significant problems. Most importantly, 30% of patients who are diagnosed with heart failure will die within 1 year and approximately 50% will die within 5 years. This condition accounts for approximately 900,000 hospitalizations annually. Among Medicare beneficiaries, the 30-day hospital r

Scholars World Heart Summit THEME: "Enlightening the Advancements and Exploring the New Horizons in Heart Care" November 18-19, 2019 | Tokyo, Japan PS:  https://scholarsconferences.com/heartcongress/ Heart Congress   aims to advance continuous medical education and encourage a nourishing exchange of facts and ideas about a healthy heart and ways to keep it healthy throughout the lifetime. This will be the best chance to impact the biggest convention of members from the  Cardiology   department. This Cardiologists Meet will see as mixture of   expert Cardiologists , Cardiac Surgeons, Interventional Cardiologists, Scientists, Researchers, Professors, Nurses, Educators, Healthcare Professionals, Physicians, Surgeons, Pharmacists, Students, Research Scholars and other Drug Manufacturing Medical Devices Companies along with various entrepreneurs and exhibitors. The   Organizing Committee  of  Heart Congress cordially invites all the people who are interested in t